Clinical efficacy of intratympanic steroid injection for treating idiopathic sudden sensorineural hearing loss

• Published in: Journal of the Chinese Medical Association Vol. 87; no. 3; pp. 328 - 333
• Main Authors: Kuo, Liang-Kuan, Wu, Jiunn-Liang, Li, Yi-Lu, Hsu, Heng-Jui
• Format: Journal Article
• Language: English
• Published: Netherlands 01.03.2024
• ISSN: 1726-4901; 1728-7731
• DOI: 10.1097/JCMA.0000000000001061

Idiopathic sudden sensorineural hearing loss (ISSNHL) is an emergency that causes permanent hearing loss if timely treatment is not provided. However, the evidence supporting the effect of intratympanic steroid injection (ITSI) starting time on hearing outcome is limited. We retrospectively enrolled 582 patients with ISSNHL who were treated with ITSIs and reviewed their clinical and audiological variables. The relationship between ITSI starting time and hearing recovery was analyzed. The mean starting time of ITSI was 13.17 ± 16.53 days. The overall hearing recovery rate was 55.15% (recovery = mean hearing level gain of ≥10 dB). The recovery rates were 79.2%, 67.4%, 50%, 36.6%, and 17.8% for the ITSI starting times of 1 to 3, 4 to 7, 8 to 14, 15 to 28, and ≥29 days, respectively. A multivariate analysis revealed that ITST starting time (odds ratio [OR] = 0.94, 95% CI, 0.92-0.96, p < 0.001) and salvage therapy (OR = 0.55, 95% CI, 0.35-0.86, p = 0.009) were independent poor prognostic factors for patients with ISSNHL. Earlier ITSI treatment is associated with a higher hearing recovery rate. Comorbidities and post-ITSI complications were nonsignificant independent risk factors.